• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    11/14/24 3:03:21 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTMX alert in real time by email
    SC 13G/A 1 cormorant-ctmx093024a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    CytomX Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    23284F105

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  23284F105
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Cormorant Asset Management, LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    IA

     
     


     

    CUSIP No.  23284F105
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Bihua Chen
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    IN
     
     


     

     

    CUSIP No. 23284F105
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    CytomX Therapeutics, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    151 Oyster Point Blvd, Suite 400

    South San Francisco, California 94080

    Item 2.(a) Names of Person Filing:

    Cormorant Asset Management, LP

    Bihua Chen

    This statement is filed by (i) Cormorant Asset Management, LP ("Cormorant"), a Delaware limited partnership, and the investment adviser to certain funds (the "Cormorant Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the Cormorant Funds and (ii) Bihua Chen ("Ms. Chen") with respect to the Shares directly held by the Cormorant Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

    Item 2.(b) Address of Principal Business Office:

    200 Clarendon Street, 52nd Floor

    Boston, MA 02116

     

    Item 2.(c) Citizenship:

    Cormorant Asset Management, LP - Delaware

    Bihua Chen - United States

     

    Item 2.(d) Title of Class of Securities

    Common Stock (the "Shares")

     

    Item 2.(e) CUSIP No.:

    23284F105

     

    CUSIP No.  23284F105
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨

    A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                             

          Not Applicable

     

    CUSIP No. 23284F105
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned

    The information set forth in Row 9 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(a) for each such Reporting Person.

    (b) Percent of class

    The information set forth in Row 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(b) for each such Reporting Person.

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    (ii) Shared power to vote or to direct the vote

    (iii) Sole power to dispose or to direct the disposition of

    (iv) Shared power to dispose or to direct the disposition of

    The information set forth in Rows 5 through 8 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(c) for each such Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a -11.

     

     
    CUSIP No. 23284F105
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Cormorant Asset Management, LP

    By: Cormorant Asset Management GP, LLC

    its General Partner

           
      By:  /s/ Bihua Chen
        Bihua Chen, Managing Member
           
     

    Bihua Chen

           
      By:  /s/ Bihua Chen
        Bihua Chen
           

     

     
    CUSIP No. 23284F105
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Cormorant Asset Management, LP

    By: Cormorant Asset Management GP, LLC

    its General Partner

           
      By:  /s/ Bihua Chen
        Bihua Chen, Managing Member
           
     

    Bihua Chen

           
      By:  /s/ Bihua Chen
        Bihua Chen
           
    Get the next $CTMX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTMX

    DatePrice TargetRatingAnalyst
    3/16/2026$12.00Neutral → Overweight
    Analyst
    1/20/2026$10.00Buy
    Guggenheim
    9/22/2025$6.00Overweight
    Cantor Fitzgerald
    9/17/2025$3.50Overweight
    Barclays
    7/31/2025$7.00Outperform
    Oppenheimer
    5/15/2025$5.00Neutral → Buy
    H.C. Wainwright
    4/14/2025$3.25 → $2.50Overweight
    Piper Sandler
    5/28/2024$2.25 → $3.50Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $CTMX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CytomX Therapeutics upgraded by Analyst with a new price target

    Analyst upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $12.00

    3/16/26 11:34:14 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on CytomX Therapeutics with a new price target

    Guggenheim initiated coverage of CytomX Therapeutics with a rating of Buy and set a new price target of $10.00

    1/20/26 9:23:09 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on CytomX Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of CytomX Therapeutics with a rating of Overweight and set a new price target of $6.00

    9/22/25 8:30:10 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    SEC Filings

    View All

    SEC Form 8-K filed by CytomX Therapeutics Inc.

    8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)

    3/19/26 4:05:37 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by CytomX Therapeutics Inc.

    424B5 - CytomX Therapeutics, Inc. (0001501989) (Filer)

    3/18/26 4:05:53 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by CytomX Therapeutics Inc.

    424B5 - CytomX Therapeutics, Inc. (0001501989) (Filer)

    3/16/26 4:37:02 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

    SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing of an underwritten public offering of 45,990,567 shares of its common stock at a price to the public of $5.30 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,179,245 shares of common stock. The gross proceeds to CytomX from the offering are expected to be $250 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, CytomX granted the underwriters a 30-day option to purchase up to an additiona

    3/17/26 10:46:40 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

    SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants. In addition, CytomX expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering m

    3/16/26 4:04:55 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

    - Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC - - Varseta-M Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Initial CX-801 PROBODY Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to host conference call today at 8 a.m. ET / 5 a.m. PT - SOUTH SAN FRANCISCO, Calif., M

    3/16/26 7:05:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chu Yu-Waye

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    3/19/26 6:41:25 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Mccarthy Sean A.

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    3/19/26 6:35:34 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Belvin Marcia

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    3/19/26 6:25:33 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Leadership Updates

    Live Leadership Updates

    View All

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

    SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Rachael Lester as Senior Vice President, Chief Business Officer. In this role, Ms. Lester will lead the Company's strategy and business development functions.   "Rachael brings a wealth of experience in strategic planning and business development across the biopharmaceutical industry and joins CytomX at a time when our platform and pipeline are well positioned to deliver meaningful advances in the treatment of many cancers," said Sean McCarthy, D.Phil., president, chief executive offic

    10/20/25 4:05:00 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

    SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company's board of directors. "We are excited to welcome Zhen to our board," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. "With his extensive experience and accomplishments in oncology, Zhen brings expertise that will help shape strategy across our multi-modality PROBODY® therapeutic pipeline as well as CytomX's continued growth an

    3/21/24 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Financials

    Live finance-specific insights

    View All

    CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

    - Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC - - Varseta-M Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Initial CX-801 PROBODY Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to host conference call today at 8 a.m. ET / 5 a.m. PT - SOUTH SAN FRANCISCO, Calif., M

    3/16/26 7:05:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

    - Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Grade 3 diarrhea rate of 10% in ongoing dose optimization cohorts - - FDA interactions targeted for mid-year with goal to align on potential registrational trial design in late-line colorectal cancer (CRC) - - Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Conference call on Monday, March 16 at 8:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics

    3/16/26 7:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

    SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year 2025 financial results on Monday, March 16, 2026, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to

    3/4/26 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:26:32 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:00:06 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 3:03:21 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care